Vaxart Stock Competitors

Vaxart (NASDAQ:VXRT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Is VXRT or IOVA more profitable?

Iovance Biotherapeutics has a net margin of 0.00% compared to Vaxart's net margin of -5,414.56%. Vaxart's return on equity of -36.10% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxart	-5,414.56%	-36.10%	-30.69%
Iovance Biotherapeutics	N/A	-45.34%	-38.91%

Does the MarketBeat Community favor VXRT or IOVA?

Iovance Biotherapeutics received 220 more outperform votes than Vaxart when rated by MarketBeat users. Likewise, 78.33% of users gave Iovance Biotherapeutics an outperform vote while only 66.67% of users gave Vaxart an outperform vote.

Company	Underperform	Outperform
Vaxart	Outperform Votes 304 66.67%	Underperform Votes 152 33.33%
Iovance Biotherapeutics	Outperform Votes 524 78.33%	Underperform Votes 145 21.67%

Do analysts prefer VXRT or IOVA?

Vaxart currently has a consensus price target of $13.75, indicating a potential upside of 116.54%. Iovance Biotherapeutics has a consensus price target of $38.20, indicating a potential upside of 103.41%. Given Vaxart's higher possible upside, analysts plainly believe Vaxart is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Iovance Biotherapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Which has better earnings and valuation, VXRT or IOVA?

Vaxart has higher revenue and earnings than Iovance Biotherapeutics. Vaxart is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxart	$4.05 million	196.77	-$32.22 million	-$0.54	-11.76
Iovance Biotherapeutics	N/A	N/A	-$259.58 million	-$2.06	-9.12

Which has more volatility and risk, VXRT or IOVA?

Vaxart has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Does the media refer more to VXRT or IOVA?

In the previous week, Vaxart had 10 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 13 mentions for Vaxart and 3 mentions for Iovance Biotherapeutics. Vaxart's average media sentiment score of 0.22 beat Iovance Biotherapeutics' score of 0.16 indicating that Vaxart is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxart	2 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals hold more shares of VXRT or IOVA?

27.8% of Vaxart shares are held by institutional investors. 3.1% of Vaxart shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vaxart beats Iovance Biotherapeutics on 9 of the 17 factors compared between the two stocks.